From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Notable Biodefense Contracts: AnaptysBio to Develop Anti-Ricin Antibodies

by Global Biodefense Staff
May 20, 2013

The U.S. federal government  has awarded a notable contract related to the field of chemical, biological, radiological and nuclear (CBRN) defense or life science research of interest for potential applications in biodefense:

AnaptysBio, Inc., a therapeutic antibody company based in San Diego, Calif., this week announced the receipt of a contract award from the U.S. government for the development of highly thermostable anti-ricin antibodies for biodefense applications. 

The contract is funded by the Defense Threat Reduction Agency (DTRA), and follows successful completion of multiple biodefense-related antibody programs by AnaptysBio in partnership with the Defense Advanced Research Projects Agency (DARPA). 

Under the terms of AnaptysBio’s contract with the Science and Technology Corporation, AnaptysBio will be responsible for delivering anti-ricin antibodies to the Edgewood Chemical and Biological Center (ECBC), an agency of the U.S. Army. 

The company’s antibody platform, known as SHM-XEL, is uniquely positioned to generate highly potent, functional antibodies for therapeutic and diagnostic uses.  Utilizing a proprietary antibody scaffold in conjunction with SHM-XEL, AnaptysBio has recently published the development of multiple full-length antibodies with unprecedented thermostability properties.  

Extended stability at room temperature conditions minimizes the cold chain dependency of antibodies, therefore reducing the logistical burden for production, distribution and storage. Such “ruggedized” antibodies are of particular utility to the military and for applications in resource-limited areas.

From Our Partners
Tags: AwardsDARPADefense Threat Reduction AgencyECBCRicinRuggedizedThermostability

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC